HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK

Katleen de Gaetano Donati, Roberto Cauda, Licia Iacoviello
  • Katleen de Gaetano Donati
    Department of Infectious Diseases- Catholic University- Rome- Italy, Italy | kdegaetanodonati@yahoo.com
  • Roberto Cauda
    Department of Infectious Diseases- Catholic University- Rome- Italy, Italy
  • Licia Iacoviello
    2Laboratory of Genetic and Environmental Epidemiology, ”John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Largo A. Gemelli 1, 86100 Campobasso, Italy, Italy

Abstract

In the last 15 years, highly active antiretroviral therapy (HAART) has determined a dramatic reduction of both morbidity and mortality in human immunodeficiency virus (HIV)-infected subjects, transforming this infection in a chronic and manageable disease. Patients surviving with HIV in the developed world, in larger number men,  are becoming aged. As it would be expected for a population of comparable age, many HIV-infected individuals report a family history of cardiovascular disease, a small proportion have already experienced a cardiovascular event and an increasing proportion has diabetes mellitus. Smoking rate is very high while an increasing proportion of HIV-infected individuals have dyslipidaemia. Studies suggest that these traditional risk factors could play an important  role in the development of cardiovascular disease in these patients as they do in the general population. Thus, whilst the predicted 10-year cardiovascular disease risk remains relatively low at present, it will likely increase in relation to the progressive aging of  this patient population. Thus, the long-term follow-up of HIV infected patients has to include co-morbidity management such as cardiovascular disease prevention and treatment. Two intriguing aspects related to the cardiovascular risk in patients with HIV infection are the matter of current investigation: 1) while these subjects share many cardiovascular risk factors with the general population, HIV infection itself increases cardiovascular risk; 2) some HAART regimens too influence atherosclerotic profile, partly due to lipid changes. Although the mechanisms involved in the development of cardiovascular complications in HIV-infected patients remain to be fully elucidated, treatment guidelines recommending interventions to prevent cardiovascular disease in these individuals are already available; however, their application is still limited.

Keywords

HIV infection; cardiovascular risk

Full Text:

PDF
HTML
Submitted: 2014-06-11 12:40:18
Published: 2010-11-10 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
199

Views:
PDF
161
HTML
2859

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Comments on this article

View all comments


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185